A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013–2019

References

• Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997–1008.
   PubMed Web of Science ®Google Scholar
• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104.
   PubMed Web of Science ®Google Scholar
• Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171–2177.
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202–205.
   PubMed Web of Science ®Google Scholar
• Chang SS, Bochner BH, Chou R, et al. Treatment of Non-Metastatic Muscle-Invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017;198(3):552–559.
   PubMed Web of Science ®Google Scholar
• Gruppe DBC. Nationale kliniske retningslinier for behandling af blaeretumorer i Danmark [cited 2021 Nov10]. Available from: http://skejby.net/Webudgaven/Pdf/DaBlaCa_april_2016.pdf.
   Google Scholar
• Gruppe DBC. Kliniske retningslinjer, behandling og opfølgning af muskelinvasiv blaerekraeft. 2020. [cited 2021 Nov 11, 10 Mar]. Available from: https://www.dmcg.dk/siteassets/kliniske-retningslinjer–-skabeloner-og-vejledninger/kliniske-retningslinjer-opdelt-pa-dmcg/blarecancer/dablaca_muskelinvasiv_1_1_admgodk111120.pdf.
   Google Scholar
• Dansk Blaere Cancer Database (DaBlaCa-Data), Årsrapport 2015. February 1, 2016. [cited 2020 Nov 10]. Available from: https://www.sundhed.dk/content/cms/86/15686_dablacadata_1–%C3%A5rsrapport_2015_til_offentligg%C3%B8relse.pdf.
   Google Scholar
• Nielsen N, Wrist Lam G, Fabrin K, et al. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy. Scand J Urol. 2019;53(4):213–216.
   PubMed Web of Science ®Google Scholar
• Hansen E, Larsson H, Norgaard M, et al. The Danish bladder cancer database. Clin Epidemiol. 2016;8:439–443.
   PubMed Web of Science ®Google Scholar
• Andersen TF, Madsen M, Jørgensen J, et al. The Danish national hospital register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263–268.
   PubMed Web of Science ®Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7 Suppl):30–33.
   PubMed Web of Science ®Google Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish national pathology registry and data bank. Clin Epidemiol. 2010;2:51–56.
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• StataCorp. Stata statistical software: Release 16. College Station, TX: StataCorp LLC. 2019.
   Google Scholar
• Schiffmann J, Sun M, Gandaglia G, et al. Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: a population-based study. CUAJ. 2016;10(3-4):82–86.
   Web of Science ®Google Scholar
• Zaid HB, Patel SG, Stimson CJ, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the national cancer database. Urology. 2014;83(1):75–80.
   PubMed Web of Science ®Google Scholar
• Hanna N, Trinh QD, Seisen T, et al. Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA. Eur Urol Oncol. 2018;1(1):83–90.
   PubMed Web of Science ®Google Scholar
• Rose TL, Deal AM, Basch E, et al. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: an evaluation of transitions between academic and community settings. Urol Oncol. 2015;33(9):386.e1-6–386.e6. Sep
   PubMed Web of Science ®Google Scholar
• Isbarn H, Karakiewicz PI, Shariat SF, et al. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol. 2009;182(2):459–465.
   PubMed Web of Science ®Google Scholar
• Volkmer BG, Kuefer R, Bartsch G, Jr, et al. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer. 2005;104(11):2384–2391.
   PubMed Web of Science ®Google Scholar
• Brant A, Kates M, Chappidi MR, et al. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: is therapeutic effect owing to chemotherapy or TURBT? Urol Oncol. 2017;35(1):34.e17-34–e25.
   Web of Science ®Google Scholar
• Iyer G, Balar AV, Milowsky MI, et al. Multicenter prospective phase II trial of neoadjuvant Dose-Dense gemcitabine plus cisplatin in patients with Muscle-Invasive bladder cancer. J Clin Oncol. 2018;36(19):1949–1956.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Coinu A, Cabiddu M, et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014;65(2):350–357.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866.
   PubMed Web of Science ®Google Scholar